These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 988093)

  • 1. [The continuous treatment of generalized myasthenia gravis with small doses of prednisolone with or wihtout immunosuppressants (author's transl)].
    Ichikawa Y; Nakata Y; Koriyama K; Komatsuda M; Arimori S
    Nihon Naika Gakkai Zasshi; 1976 Jul; 65(7):669-80. PubMed ID: 988093
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of myasthenia gravis with immunosuppressants (author's transl)].
    Yang RM
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Feb; 14(1):23-5. PubMed ID: 7307783
    [No Abstract]   [Full Text] [Related]  

  • 3. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
    Ponseti JM; Azem J; Fort JM; Codina A; Montoro JB; Armengol M
    Clin Neurol Neurosurg; 2005 Apr; 107(3):187-90. PubMed ID: 15823673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose tacrolimus for intractable myasthenia gravis.
    Yoshikawa H; Mabuchi K; Yasukawa Y; Takamori M; Yamada M
    J Clin Neurosci; 2002 Nov; 9(6):627-8. PubMed ID: 12604270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone density in myasthenia gravis patients receiving long-term prednisolone therapy.
    Wakata N; Nemoto H; Sugimoto H; Nomoto N; Konno S; Hayashi N; Araki Y; Nakazato A
    Clin Neurol Neurosurg; 2004 Mar; 106(2):139-41. PubMed ID: 15003307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for the clinical guidelines for myasthenia gravis in Japan.
    Murai H; Utsugisawa K; Nagane Y; Suzuki S; Imai T; Motomura M
    Ann N Y Acad Sci; 2018 Feb; 1413(1):35-40. PubMed ID: 29377151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long term administration of oral prednisone or prednisolone in treatment of myasthenia gravis. Report of five cases (author's transl)].
    Contamin F; Singer B; Mignot B; Offenstadt G; Ecoffet M
    Sem Hop; 1978 Nov 18-25; 54(41-42):1213-8. PubMed ID: 216096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil - as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience.
    Prakash KM; Ratnagopal P; Puvanendran K; Lo YL
    J Clin Neurosci; 2007 Mar; 14(3):278-81. PubMed ID: 16597503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis.
    Nakamura S; Kaneko S; Shinde A; Morita J; Fujita K; Nakano S; Kusaka H
    Neuromuscul Disord; 2013 Feb; 23(2):176-9. PubMed ID: 23237872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Immunosuppressive Treatment of Myasthenia Gravis in Denmark: A Nationwide Drug Utilization Study, 1996-2013.
    Pedersen EG; Hallas J; Pottegård A; Hald SM; Jensen PEH; Gaist D
    Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):486-493. PubMed ID: 29732733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.
    Palace J; Newsom-Davis J; Lecky B
    Neurology; 1998 Jun; 50(6):1778-83. PubMed ID: 9633727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with prednisolone and tacrolimus for myasthenia gravis with invasive thymoma.
    Miura S; Azuma K; Yamada K; Takamori S; Kawahara A; Noda K; Ayabe M; Kage M; Aizawa H; Taniwaki T
    Acta Neurol Belg; 2010 Mar; 110(1):107-9. PubMed ID: 20514937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of myasthenia gravis by long-term alternate-day prednisolone.
    Chen RC; Sung SM; Soong WT; Ryu SJ; Sun JL; Hung TP
    Taiwan Yi Xue Hui Za Zhi; 1975 Sep; 74(9):579-89. PubMed ID: 1062502
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunosuppressant drugs for myasthenia gravis.
    Hart IK; Sharshar T; Sathasivam S
    J Neurol Neurosurg Psychiatry; 2009 Jan; 80(1):5-6; discussion 6. PubMed ID: 19091704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early aggressive treatment strategy against myasthenia gravis.
    Nagane Y; Suzuki S; Suzuki N; Utsugisawa K
    Eur Neurol; 2011; 65(1):16-22. PubMed ID: 21116111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immuno suppressive drugs in the treatment of myasthenia (author's transl)].
    Buscaino GA
    Riv Patol Nerv Ment; 1974 Aug; 95(4):399-410. PubMed ID: 4377801
    [No Abstract]   [Full Text] [Related]  

  • 17. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone.
    Shimojima Y; Matsuda M; Gono T; Ishii W; Tokuda T; Ikeda S
    J Clin Neurosci; 2006 Jan; 13(1):39-44. PubMed ID: 16307880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent long-term adrenocorticosteroid treatment of myasthenia gravis.
    Wakata N; Kawamura Y; Kobayashi M; Araki Y; Kinoshita M
    J Neurol; 1991 Feb; 238(1):16-8. PubMed ID: 2030367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus).
    Konishi T; Yoshiyama Y; Takamori M; Saida T
    J Neurol Neurosurg Psychiatry; 2005 Mar; 76(3):448-50. PubMed ID: 15716549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Massive prednisolone administration in myasthenia gravis--electrophysiological examination].
    Yanagizawa N; Shoji S; Tsukagoshi H; Toyokura Y
    Nihon Rinsho; 1973 Feb; 31(2):321-6. PubMed ID: 4737112
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.